Akebia Therapeutics, Inc. (AKBA)
Develops kidney disease medications to treat anemia and iron deficiency in dialysis patients.
$1.27-0.01%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-65.9%
The outlook
AKBA is trading near its 52-week lows at $1.27, with analyst sentiment bearish overall despite an average price target suggesting significant upside from current levels. The stock sits well below its moving averages, reflecting mixed momentum, though analyst coverage appears to lean optimistic on longer-term valuation.
What’s behind the score
Price trendMixed vs its moving averages
52-week range15% of the way from its 52-week low to high
Price targetAvg target +231% vs current price
Analyst price target
~12-month · 5 analysts$4.20average target+230.7% vs now
Now $1.27
Low $3.00High $6.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$340.7M
52-wk high
$3.81
52-wk low
$0.82
50-day avg
$1.13
200-day avg
$1.50
Trailing P/E
—